Efficacy and safety of thalidomide in patients with hepatocellular carcinoma

Table 7 Correlation between thalidomide-related adverse events and comorbidity

	Comorbidity (n)		P
	Absent	Present
Without adverse events	4	2	0.021
With adverse drug eventsa	6	30
Adverse events per patientc	1.1 ± 1.2	2.2 ± 1.3	0.022

^aP < 0.05,

^cP < 0.05 vs without adverse events, between groups of with comorbidity and without comorbidity.